BioMed News Bytes: GeoVax (OTC: GOVX.OB), Nutra Pharma (OTC: NPHC.OB) Print E-mail
Monday, 21 September 2009 10:54
On 9/21/09, GeoVax Labs (OTC: GOVX.OB) ($0.19, +39%, heavy volume) announced that it has requested a pre-Investigational New Drug (IND) meeting with the FDA to discuss a proposed IND for clinical testing of the Company’s therapeutic vaccine as a treatment for individuals infected with HIV / AIDS.


GeoVax stated that the FDA has 60 days (i.e. 11/20/09) from its submission to review the proposal and respond with questions or comments.


The proposed human clinical trial is based on the achievement of excellent post vaccine viral control in animal trials conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University and follows the precedents set in preclinical animal trials. Submission of a request to the FDA for a pre-IND meeting is the first step in a process that is expected to take a number of months to complete with commencement of the trial targeted for 1Q10.


On 9/21/09, Nutra Pharma (OTC: NPHC.OB) ($0.60, +29%, heavy volume) announced that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The Company is currently marketing a similar drug in the U.S. under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain. Nutra Pharma stated that it is confident that its pain reliever can be successfully registered in the near term based on the regulatory requirements in Canada and Europe, with estimated populations exceeding 33 million and 830 million, respectively.


In August, Nutra Pharma introduced Cobroxin as the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available in October as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. In addition, the Company recently completed a licensing agreement that grants XenaCare (OTCBB: XCHO.OB) with the exclusive marketing and distribution rights to Cobroxin within the U.S.


Disclosure: No positions.


See my full disclaimer at (bottom of any page).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus